Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart

Journal of Molecular and Cellular Cardiology

Volumn 29, Issue 11, 1997, Pages 3135-3146

  Kostic, M M ^c   Erdogan, S ^b   Rena, G ^b   Borchert, G ^a   Hoch, B ^a   Bartel, S ^a   Scotland, G ^b   Huston, E ^b   Houslay, M D ^b   Krause, E G ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c NONE

Author keywords

7 oxo prostacyclin; Cyclic nucleotide phosphodiesterases (PDE1 and PDE4); Myocardial preconditioning; RT PCR; Splice variants

Indexed keywords

7 OXOPROSTACYCLIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE IV;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART PROTECTION; IMMUNOBLOTTING; MALE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031281531     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1997.0544     Document Type: Article

References (54)

1. ALVAREZ R, SETTE C, YANG D, EGLEN RM, WILHELM R, SHELTON ER, CONTI M, 1995. Activation and selective inhibition of cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol 48: 616-622.
2. BEAVO JA, 1995. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725-748.
3. BODE DC, KANTER JR, BRUNTON LL, 1991. Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. Circ Res 68: 1070-1079.
4. BOLGER G, MICHAELI T, MARTINS T, STJOHN T, STEINER B, RODGERS L, RIGGS M, WIGLER M, FERGUSON K, 1993. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13: 6558-6571.
5. BOLGER GB, 1994. Molecular biology of cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Sign 6: 851-859.
6. BORCHERT G, BARTEL S, BEYERDORFER I, KUTTNER I, SZEKERES L, KRAUSE EG, 1994. Long lasting antiadrenergic effect of 7-oxo-prostacyclin in the heart: a cycloheximide sensitive increase of phosphodiesterase isoform I and IV activities. Mol Cell Biochem 132: 57-67.
7. BRADFORD MM, 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
8. BROWN T, 1994. Analysis of RNA by Northern and slot blot hybridization. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Struhl K (eds). Current Protocols in Molecular Biology, Suppl. 23. New York: John Wiley & Sons, Inc., 4.9.1-4.9.14.
9. BUXTON IL, BRUNTON LL, 1983. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem 258: 10233-10239.
10. CASTIELLA E, FRECHILLA D, LASHERAS B, CENARRUZABETIA E, MARTINES DE-IRNJO II, ALBERDI E, SANTIAGO E, MONGE A, VILLANNEVA A, MARTINEZ FJ, 1995. Inotropic and chronotropic effects of 4-(4′-n-butylaniline)-7,8-dimethoxy-5H-pyrimido[5,4-b] induce in guinea-pig atria. J Pharm Pharmacol 47: 601-607.
11. CONTI M, NEMOZ G, SETTE C, VICINI E, 1995. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrine Rev 16: 370-389.
12. DAVIS CW, 1984. Assessment of selective inhibition of rat cerebral cortical calcium-dependent and calcium independent phosphodiesterases in crude extracts using deoxy cyclic AMP and potassium ions. Biochim Biophys Acta 797: 354-362.
13. +)ATPase. Cardioscience 2: 105-108.
14. ERDOGAN S, HOUSLAY MD, 1997. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cyclic AMP phosphodiesterase expression by upregulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as downregulating a novel PDE4A splice variant. Biochem J 321: 165-175.
15. HOSHIDA S, KUZUYA T, FUJU H, YAMASHITA N, OE H, HORI M, SUZUKI K, TANIGUVCHI N, TADA M, 1993. Sublethal ischemia alters myocardial antioxidant activity in canine heart. Am J Physiol 264: H33-H39.
16. HOUSLAY MD, MILLIGAN G, 1997. Tailoring cAMP-signalling responses through isoform multiplicity. TIBS 22: 217-224.
17. HOVE-MADSEN L, MERY PF, JUREVICIUS J, SKEBERDIS AV, FISCHMEISTER R, 1996. Regulation of myocardial calcium channels by cyclic AMP metabolism. Basic Res Cardiol 91: 1-8.
18. HUSTON E, POOLEY L, JULIEN P, SCOTLAND G, MCPHEE I, SULLIVAN M, BOLGER G, HOUSLAY MD, 1996. The human cyclic AMP-speciflc phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species which exhibit distinct kinetics of inhibition by the anti-depressant rolipram. J Biol Chem 271: 31334-31344.
19. HUSTON E, LUMB S, RUSSELL A, CATTERALL C, ROSS AH, STEELE MR, BOLGER GB, PERRY MJ, OWENS RJ, HOUSLAY MD. 1997 Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cyclic AMP specific phosphodiesterase, HSPDE4B3. Biochem J (in press).
20. 2 and PGE2 on cardiac hemodynamic and coronary arterial and myocardial cyclic nucleotide levels in dog. Jpn Circ J 44: 755-761.
21. KAKIUCHI S, YAMAZAKI R, TESHIMA Y, UENISHI K, MIYAMOTO E, 1975. Multiple cyclic nucleotide phosphodiesterase activities from rat tissues and occurrence of calcium-plus-magnesium-ion-dependent phosphodiesterase and its protein activator. Biochem J 146: 109-120.
22. KINGSTON RE, CHOMCZYNSKI P, SACCHI N, 1994. Guanidinium methods for total RNA preparation. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Struhl K (eds). Current Protocols in Molecular Biology, Suppl. 23. New York: John Wiley & Sons, Inc., 4.2.1-4.2.8.
23. KLEE CB, VANAMAN TC, 1982. Calmodulin. Adv Prot Chem 35: 213-321.
24. KRAUSE EG, SZEKERES L, 1995. On the mechanism and possible therapeutic application of delayed adaptation of the heart to stress situations. Mol Cell Biochem 147: 115-122.
25. KUZUYA T, HOSHIDA S, YAMASHITA N, FUI H, OE H, HORI M, KAMADA T, TADA M, 1993. Delayed effect of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 72: 1293-1299.
26. LAEMMLI UK, 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (London) 222: 680-682.
27. LOBBAN M, SHAKUR Y, BEATTIE J, HOUSLAY MD, 1994. Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localisation in membrane and cytosolic compartments and differential expression in various brain regions. Biochem J 304: 399-406.
28. LOUGHNEY K, MARTINS TJ, HARRIS EAS, SADHU K, HICKS JB, SONNENBURG WK, BEAVO JA, FERGUSON K, 1996. Isolation and characterisation of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases. J Biol Chem 271: 796-806.
29. LUGNIER C, GANTHIER C, BEC AL, SOUSTRE H, 1992. Cyclic nucleotide phosphodiesterase from frog atrial fibres: isolation and drug sensitivities. Am J Physiol 262: H654-H660.
30. MARBER MS, LATCHMAN DS, WALKER JM, YELLON DM, 1993. Cardiac stress protein elevation 24 hours after brief heat stress is associated with resistance to myocardial infarction. Circulation 88: 1264-1272.
31. McPHEE I, POOLEY L, LOBBAN M, BOLGER G, HOUSLAY MD, 1995. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem J 310: 965-974.
32. MONACO L, VICINI E, CONTI M, 1994. Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites. J Biol Chem 269: 347-357.
33. NEMOZ G, SETTE C, HESS M, MUCA C, VALLAR L, CONTI M, 1995. Activation of cyclic nucleotide phosphodiesterases in FRTL-5 thyroid cells expressing a constitutively active Gs alpha. Mol Endocrinol 9: 1279-1287.
34. NEMOZ G, ZHANGB, SETTE C, CONTI M, 1996. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett 384: 97-102.
35. OKRUHLICOVA L, TRIBULOVA N, ECKLY A, LUGNIER C, SLEZAK J, 1996. Cytochemical distribution of cyclic AMP-dependent 3′,5′-nucleotide phosphodiesterase in the rat myocardium. Histochem J 28: 165-172.
36. PARRATT JR, 1995. Possibilities for the pharmacological exploitation of ischaemic preconditioning. J Mol Cell Cardiol 27: 991-1000.
37. PICQ M, DUBOIS M, GRYNBERG A, LAGARDE M, PRIGENT AF, 1995. Developmental differences in distribution of cyclic nucleotide phosphodiesterase isoforms in cardiomyocytes and the ventricular tissue from newborn and adult rats. J Cardiovasc Pharmacol 26: 742-750.
38. PODZUWEIT T, NENNSTIEL P, MÜLLER A, 1995. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterase by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Sign 7: 733-738.
39. REEVES ML, LEIGH BK, ENGLAND P, 1987. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig heart. Biochem J 241: 535-541.
40. SCHWABE U, MIYAKE M, OHGA Y, DALY JW, 1976. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2 pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′-5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 12: 900-910.
41. SHAKUR Y, WILSON M, POOLEY L, LOBBAN M, GRIFFITHS SL, CAMPBELL AM, BEATTIE J, DALY C, HOUSLAY MD, 1995. Identification and characterization of the type-IVA cyclic AMP-speciflc phosphodiesterase RDI as membrane-bound protein expressed in cerebellum. Biochem J 306: 801-809.
42. 2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. Biochem J 310: 975-982.
43. SPENCE S, RENA G, SULLIVAN M, ERDOGAN S, HOUSLAY MD, 1997. Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of calcium/calmodulin stimulated cAMP phosphodiesterase. Biochem J 321: 157-163.
44. STOCLET JC, KERAVIS T, KOMAS N, LUGNIER C, 1995. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases. Exp Opin Invest Drugs 4: 1081-1100.
45. 2 analogue 7-oxo-prostacyclin-Na in experimental model angina in dogs (Abstract). J Mol Cell Cardiol 15 (Suppl. 3): 394.
46. 2 and its possible mode of action. Biomed Biochim Acta 43: 135-142.
47. TENOR H, BARTEL S, KRAUSE E-G, 1987. Cyclic nucleotide phosphodiesterase in the rat myocardium: evidence of four different PDE isotypes. Biomed Biochim Acta 46: S749-S753.
48. THOMPSON WJ, 1991. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther 51: 13-33.
49. VEGH A, PAPP JG, KASALA K, PARRATT JR, 1994a. Cardiac pacing in anesthetised dogs preconditions the heart against arrhythmias when ischemia is induced 24 h later. J Physiol 480: 89P.
50. VEGH A, PAPP JG, PARRATT JR, 1994b. Dexamethasone prevents the marked antiarrhythmic effects of preconditioning induced twenty hours after rapid cardiac pacing. Br J Pharmacol 113: 1081-1083.
51. Wang P, MYERS JG, WU P, CHEEWATRAKOOLPONG B, EGAN RW, BILLAH MM, 1997. Expression, purification, and characterization of human cAMP-speciflc phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochim Biophys Res Commun 234: 320-324.
52. WEISHAAR RE, CAIN MH, BRISTOL JA, 1985. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 28: 537-545.
53. WEISHAAR RE, KOBYLARZ-SINGER DC, KAPLAN HR, 1987. Subclasses of cyclic AMP phosphodiesterase in cardiac muscle. J Mol Cell Cardiol 19: 1025-1036.
54. YAN C, ZHAO AZ, BENTLEY JK, LOUGHNEY K, FERGUSON K, BEAVO J, 1995. Molecular cloning and characterisation of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Natl Acad Sci USA 92: 9677-9681.